Hepatic Targeting of the Centrally Active Cannabinoid 1 Receptor (CB1R) Blocker Rimonabant Via PLGA Nanoparticles for Treating Fatty Liver Disease and Diabetes
JOURNAL OF CONTROLLED RELEASE（2023）
Key words
CB1 receptor blocker,Obesity,Hepatic steatosis,Insulin resistance,Drug delivery system,Polymeric nanoparticles,Nanomedicine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined